FLT4 and in situ carcinoma: As follows from Figure 16A, FLT4- and MET-expressing cells were very rare among CD45-negative cell subset of the control samples and HPV(+) benign lesions/CIN1, while in high-grade lesions or carcinoma in situ we detected a noticeable increase in their numbers (p < 0.05, U-test), which became even higher in invasive stage IA cervical cancer; however, the difference between CIN3/cancer in situ and cancer stage IA was statistically confirmed only for MET (p < 0.05, U-test).